Stayble Therapeutics visited the Bio International Convention in Boston
As part of Stayble Therapeutics’ (“Stayble”) strategy to find a development partner, the company participated in the international Bio International Convention in Boston last week. During the convention, Stayble presented to several potential partners who could bring Stayble's drug candidate to the market.
For four days, June 5-8, Stayble's CEO Andreas Gerward and COO Mattias Münnich attended the Bio International Convention to network and present Stayble's drug candidate. The purpose of Stayble's participation was to follow up on existing contacts and identify additional interesting partnering companies with the ability to take the drug candidate STA363 through phase III and market approval.
Andreas Gerward, CEO of Stayble, comments:
"It has been inspiring to be in Boston. We have had about 30 meetings and met with companies from Europe, USA, Japan, South Korea and China who are all interested in our concept. At this stage, we have met with partners to assess their interest and capacity and prepare them for top-line data in the fourth quarter of this year. We are looking for both global and local partnering companies. The important thing is that a partner has the proper development capacity as well as the right commercial capacity and knowledge of the dynamics of the geographical markets they operate in. As we have come a long way in our clinical development and offer a project with a huge market potential, the interest during the convention has been great and assuming positive data in Q4, we see that there are several possible partner deals that would all mean a good deal for Stayble's investors."
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. Aimed at patients who are not helped by physiotherapy and painkillers, the treatment is a single injection that is expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is currently conducting a Phase 2b clinical trial in DDD and a Phase Ib trial in LDH.
Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.